The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels
Open accessAbstract
The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but liver-related morbidity rates remain high, given notoriously low uptake of HCV treatment. Advances in HCV therapy will have a limited impact on the burden of HCV-related disease at the population-level unless barriers to HCV education, screening, evaluation, and treatment are addressed and treatment uptake increases. This review will outline barriers to HCV care in HCV/HIV coinfection, with a particular emphasis on persons who inject drugs, proposing strategies to enhance HCV treatment uptake and outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonner, J. E., Barritt, A. S., Fried, M. W., & Evon, D. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2141-4 · Cited by 32
Research works printed but not linked: 33
- Taylor, 2012, HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms, Clin Infect Dis, 55, S33, 10.1093/cid/cis367 · DOI
- Thomas, 2011, Hepatitis C in HIV-infected individuals: cure and control, right now, J Int AIDS Soc, 14, 22, 10.1186/1758-2652-14-22 · DOI
- Kim, 2012, An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection, J Infect Dis
- Grebely, 2011, Management of HCV and HIV infections among people who inject drugs, Curr Opin HIV AIDS, 6, 501, 10.1097/COH.0b013e32834bcb36 · DOI
- Hellard, 2009, Hepatitis C treatment for injection drug users: a review of the available evidence, Clin Infect Dis, 49, 561, 10.1086/600304 · DOI · Paper page
- Martin, 2011, Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility, J Hepatol, 54, 1137, 10.1016/j.jhep.2010.08.029 · DOI · Paper page
- Martin, 2012, Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations, Hepatology, 55, 49, 10.1002/hep.24656 · DOI · Paper page
- Grebely, 2009, Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents, J Viral Hepat, 16, 352, 10.1111/j.1365-2893.2009.01080.x · DOI · Paper page
- Mehta, 2006, Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic, AIDS, 20, 2361, 10.1097/QAD.0b013e32801086da · DOI
- Fishbein, 2004, Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection, J Acquir Immune Defic Syndr, 37, 1367, 10.1097/01.qai.0000131932.21612.49 · DOI
- Grebely, 2008, Barriers associated with the treatment of hepatitis C virus infection among illicit drug users, Drug Alcohol Depend, 93, 141, 10.1016/j.drugalcdep.2007.09.008 · DOI · Paper page
- Swan, 2010, Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration, AIDS Patient Care STDS, 24, 753, 10.1089/apc.2010.0142 · DOI · Paper page
- Myles, 2011, Physicians’ attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada, Can J Gastroenterol, 25, 135, 10.1155/2011/810108 · DOI
- Litwin, 2007, Hepatitis C management by addiction medicine physicians: results from a national survey, J Subst Abuse Treat, 33, 99, 10.1016/j.jsat.2006.12.001 · doi:10.1016/j.jsat.2006.12.001
- Lambert, 2011, General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting, Aust J Prim Health, 17, 282, 10.1071/PY10069 · doi:10.1071/py10069
- Osilla, 2011, Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment, AIDS Patient Care STDS, 25, 533, 10.1089/apc.2011.0048 · doi:10.1089/apc.2011.0048
- Oser, 2012, Correlates of hazardous drinking among veterans with and without hepatitis C, J Behav Med, 35, 634, 10.1007/s10865-011-9394-9 · DOI
- Wagner, 2009, Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection, AIDS Patient Care STDS, 23, 715, 10.1089/apc.2009.0049 · DOI
- Treloar, 2012, Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs, Drug Alcohol Rev, 31, 918, 10.1111/j.1465-3362.2012.00468.x · doi:10.1111/j.1465-3362.2012.00468.x
- Osilla, 2009, Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment, AIDS Patient Care STDS, 23, 993, 10.1089/apc.2009.0153 · DOI
- Treloar, 2010, Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals, J Viral Hepat, 17, 839, 10.1111/j.1365-2893.2009.01250.x · DOI
- Ward, 2012, Hepatitis C virus prevention, care, and treatment: from policy to practice, Clin Infect Dis, 55, S58, 10.1093/cid/cis392 · DOI
- Litwin, 2012, Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk, Dig Liver Dis, 44, 497, 10.1016/j.dld.2011.12.014 · DOI
- Rockstroh, 2008, European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults, HIV Med, 9, 82, 10.1111/j.1468-1293.2007.00535.x · DOI · Paper page
- Arora, 2011, Outcomes of treatment for hepatitis C virus infection by primary care providers, N Engl J Med, 364, 2199, 10.1056/NEJMoa1009370 · DOI · Paper page
- McGovern, 2012, Editorial commentary: hepatitis C virus and the infectious disease physician: a perfect match, Clin Infect Dis, 55, 414, 10.1093/cid/cis378 · doi:10.1093/cid/cis378
- Knott, 2006, Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes, Am J Gastroenterol, 101, 2254, 10.1111/j.1572-0241.2006.00731.x · DOI
- Larrey, 2011, Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-alpha2a and ribavirin, Clin Gastroenterol Hepatol, 9, 781, 10.1016/j.cgh.2011.05.022 · DOI
- Grebely, 2007, Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users, J Gastroenterol Hepatol, 22, 1519, 10.1111/j.1440-1746.2007.05032.x · DOI
- Grebely, 2010, Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support, Eur J Gastroenterol Hepatol, 22, 270, 10.1097/MEG.0b013e32832a8c4c · DOI
- Sylvestre, 2007, Integrating HCV services for drug users: a model to improve engagement and outcomes, Int J Drug Policy, 18, 406, 10.1016/j.drugpo.2007.01.010 · DOI
- Norman, 2008, The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users, Harm Reduct J, 5, 8, 10.1186/1477-7517-5-8 · doi:10.1186/1477-7517-5-8
- Dore, 2012, The changing therapeutic landscape for hepatitis C, Med J Aust, 196, 629, 10.5694/mja11.11531 · doi:10.5694/mja11.11531
Metadata
- Authors
- Grebely, J., Oser, M., Taylor, L. E., & Dore, G. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-03-15
- Volume
- 207
- Issue
- suppl_1
- Pages
- S19-S25
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2117027295
- Cited by
- 182
- References
- 1
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. https://app.cochat.ai/papers/10.1093/infdis/jis928
- The paper
- Grebely, J., Oser, M., Taylor, L. E., & Dore, G. J. (2013). Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jis928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.